June 2020
Volume 61, Issue 7
Open Access
ARVO Annual Meeting Abstract  |   June 2020
Ranibizumab or Aflibercept for Diabetic Macular Edema: One-Year Comparison of Real-World Outcomes from Fight Retinal Blindness! Registry.
Author Affiliations & Notes
  • SANJEEB BHANDARI
    The University of Sydney, Save Sight Institute, Sydney, New South Wales, Australia
  • Vuong Nguyen
    The University of Sydney, Save Sight Institute, Sydney, New South Wales, Australia
  • Samantha Fraser-Bell
    The University of Sydney, Save Sight Institute, Sydney, New South Wales, Australia
  • Hemal Mehta
    The University of Sydney, Save Sight Institute, Sydney, New South Wales, Australia
    Ophthalmology Department, Royal Free London NHS Foundation Trust, London, United Kingdom
  • Francesco Viola
    Fondazione Cà Granda Ospedale Maggiore Policlinico, University of Milan, Milan, Italy, Milan, Italy
  • Florian Baudin
    Department of Ophthalmology, Dijon University Hospital, Dijon, France
  • Pierre-Henry Gabrielle
    Department of Ophthalmology, Dijon University Hospital, Dijon, France
  • Catherine P Creuzot Garcher
    Department of Ophthalmology, Dijon University Hospital, Dijon, France
  • Mark C Gillies
    The University of Sydney, Save Sight Institute, Sydney, New South Wales, Australia
  • Daniel Barthelmes
    The University of Sydney, Save Sight Institute, Sydney, New South Wales, Australia
    Department of Ophthalmology, University Hospital Zurich, University of Zurich, Zurich, Switzerland
  • Footnotes
    Commercial Relationships   SANJEEB BHANDARI, None; Vuong Nguyen, None; Samantha Fraser-Bell, Allergan (R), Bayer (R), Novartis (R); Hemal Mehta, Allergan (R), Bayer (R), Novartis (R), Roche (R); Francesco Viola, Bayer (R), Novartis (R), Roche (R); Florian Baudin, None; Pierre-Henry Gabrielle, None; Catherine Creuzot Garcher, Allergan (S), Bausch and Lomb (S), Bayer (S), Novartis (S), Roche (S); Mark Gillies, Allergan (S), Allergan (R), Bayer (S), Bayer (R), Novartis (S), Novartis (R), Roche (S), Roche (R); Daniel Barthelmes, Bayer (R), Novartis (R)
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science June 2020, Vol.61, 3289. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      SANJEEB BHANDARI, Vuong Nguyen, Samantha Fraser-Bell, Hemal Mehta, Francesco Viola, Florian Baudin, Pierre-Henry Gabrielle, Catherine P Creuzot Garcher, Mark C Gillies, Daniel Barthelmes; Ranibizumab or Aflibercept for Diabetic Macular Edema: One-Year Comparison of Real-World Outcomes from Fight Retinal Blindness! Registry.. Invest. Ophthalmol. Vis. Sci. 2020;61(7):3289.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : To compare the 12 months treatment outcomes of ranibizumab and aflibercept for diabetic macular edema (DME) in routine clinical practice.

Methods : This was a retrospective analysis of data from a prospectively designed observational registry: the Fight Retinal Blindness! Project. Treatment-naïve eyes that started either ranibizumab (0.5mg) or aflibercept (2mg) for DME from 1 December 2013 to 1 June 2018 were identified. The primary outcome was the mean change in visual acuity (VA in logMAR letters) from baseline to 12 months.

Results : We identified 383 eyes (Ranibizumab – 166, Aflibercept – 217) of 291 patients. Eyes of patients in the aflibercept group had a lower mean VA (mean difference [MD] -3.1 letters) and a thicker maculae (MD +26μm) than those of ranibizumab at baseline which was not significantly different (Table 1). Patients on ranibizumab were older (MD +2.7 years). The adjusted MD in VA change and central subfield thickness (CST) reduction were +1 letter (1.4 for aflibercept versus 0.4 for ranibizumab, p=0.4) and -30 microns (-85 versus -55, p<0.01) in eyes with initial VA ≥20/40 and +3 letters (10.6 versus 7.6, p<0.01) and -46 microns (-148 versus -102, p<0.02) in those presenting with VA ≤20/50. Eyes in the aflibercept group received more injections over 12 months, median (Q1, Q3) of 8 (6, 9), than the ranibizumab group, 6 (4, 8), though this difference was not significant (p=0.13). Treatment switches, albeit low, were more frequent from ranibizumab to aflibercept than vice versa. Significantly more eyes in the aflibercept group were lost to follow-up within 12 months (21% versus 9% ranibizumab, P<0.01).

Conclusions : Both drugs were beneficial for DME (Figure 1). Aflibercept-treated eyes, which had borderline worse vision and thicker maculae at baseline, had larger reductions in CST after 12 months of treatment. Larger gains in VA was observed with aflibercept treatment when the initial VA was ≤20/50.

This is a 2020 ARVO Annual Meeting abstract.

 

 

Figure 1. Line graphs showing (A) the mean predicted VA (solid lines) in logMAR letters (y-axis) and CST (dashed lines) in μm (z-axis); (B) the difference in the mean change in VA and (C) CST between ranibizumab (purple) and aflibercept (blue) treated eyes over 12-month in all eyes irrespective of whether they completed, switched (visits at the time of switch) or did not complete 12-month observation from starting treatment.

Figure 1. Line graphs showing (A) the mean predicted VA (solid lines) in logMAR letters (y-axis) and CST (dashed lines) in μm (z-axis); (B) the difference in the mean change in VA and (C) CST between ranibizumab (purple) and aflibercept (blue) treated eyes over 12-month in all eyes irrespective of whether they completed, switched (visits at the time of switch) or did not complete 12-month observation from starting treatment.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×